The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. Long-term survival of patients with AML has changed little over the past decade, necessitating the identification and validation of new AML targets. Integration of genomic approaches with small-molecule and genetically based high-throughput screening holds the promise of improved discovery of candidate targets for cancer therapy. Here, we identified a role for glycogen synthase kinase 3α (GSK-3α) in AML by performing 2 independent small-molecule library screens and an shRNA screen for perturbations that induced a differentiation expression signature in AML cells. GSK-3 is a serine-threonine kinase involved in diverse cellular processes, including differentiation, signal transduction, cell cycle regulation, and proliferation. We demonstrated that specific loss of GSK-3α induced differentiation in AML by multiple measurements, including induction of gene expression signatures, morphological changes, and cell surface markers consistent with myeloid maturation. GSK-3α-specific suppression also led to impaired growth and proliferation in vitro, induction of apoptosis, loss of colony formation in methylcellulose, and anti-AML activity in vivo. Although the role of GSK-3β has been well studied in cancer development, these studies support a role for GSK-3α in AML.

[1]  David Baltimore,et al.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.

[2]  S. Adachi,et al.  Apoptosis Induced by Molecular Targeting Therapy in Hematological Malignancies , 2003, Acta Haematologica.

[3]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[4]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[5]  B. Doble,et al.  Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. , 2007, Cell metabolism.

[6]  K. Cadigan,et al.  How do they do Wnt they do?: regulation of transcription by the Wnt/β‐catenin pathway , 2012, Acta physiologica.

[7]  Todd R Golub,et al.  Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation , 2004, Nature Genetics.

[8]  L. Trentin,et al.  Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death , 2010, BMC Cancer.

[9]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[10]  Yong-Jun Jiang,et al.  Structural Features Underlying Selective Inhibition of GSK3β by Dibromocantharelline: Implications for Rational Drug Design , 2011, Chemical Biology and Drug Design.

[11]  A. Massari,et al.  PREVENTION OF ANTIBLASTIC NEUTROPENIA WITH LITHIUM CARBONATE , 1979, The Lancet.

[12]  P. Cohen,et al.  The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.

[13]  J. Woodgett,et al.  Glycogen Synthase Kinase-3&agr; Limits Ischemic Injury, Cardiac Rupture, Post–Myocardial Infarction Remodeling and Death , 2011, Circulation.

[14]  C. So,et al.  β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. , 2010, Cancer cell.

[15]  M. Oya,et al.  Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma , 2009, British Journal of Cancer.

[16]  P. Fletcher,et al.  Abnormalities in brain structure and behavior in GSK-3alpha mutant mice , 2009, Molecular Brain.

[17]  R. Moon,et al.  Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation , 2006, Nature Medicine.

[18]  N. Friedman,et al.  Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis , 2011, Cell.

[19]  H. Manji,et al.  Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. , 2004 .

[20]  O. Abdel-Wahab,et al.  Recent advances in the treatment of acute myeloid leukemia , 2010, F1000 medicine reports.

[21]  A. Barrett,et al.  LITHIUM IN ACUTE MYELOID LEUKÆMIA , 1977, The Lancet.

[22]  Dexin Kong,et al.  Advances in development of phosphatidylinositol 3-kinase inhibitors. , 2009, Current medicinal chemistry.

[23]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[24]  I. Weissman,et al.  Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation , 2009, Proceedings of the National Academy of Sciences.

[25]  Robert Lindeman,et al.  Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth. , 2010, Experimental hematology.

[26]  T. Golub,et al.  A method for high-throughput gene expression signature analysis , 2006, Genome Biology.

[27]  Pranela Rameshwar,et al.  Distinct Roles of Glycogen Synthase Kinase (GSK)-3α and GSK-3β in Mediating Cardiomyocyte Differentiation in Murine Bone Marrow-derived Mesenchymal Stem Cells* , 2009, The Journal of Biological Chemistry.

[28]  W. Tong,et al.  Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. , 2009, The Journal of clinical investigation.

[29]  Mark J. Murphy,et al.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.

[30]  R. G. Brown,et al.  The clinical laboratory and electroencephalographic effects of lithium. , 1966, Journal of psychiatric research.

[31]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[32]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[33]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[34]  D. Charron,et al.  Double-blind, placebo-controlled lithium treatment in chemotherapy induced aplasia for AML: Reduced antibiotic requirement , 1988, Medical oncology and tumor pharmacotherapy.

[35]  J. Lefante,et al.  Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia A Southeastern Cancer Study Group study , 1984, American journal of clinical oncology.

[36]  Philip Cohen,et al.  GSK3 takes centre stage more than 20 years after its discovery. , 2001 .

[37]  Tina N. Davis,et al.  Proteomic and genetic approaches identify Syk as an AML target. , 2009, Cancer cell.

[38]  J. Woodgett,et al.  Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes , 2008, Expert opinion on therapeutic targets.

[39]  D. Brahams.  AIDS in the United States: Education and Litigation , 1988, The Lancet.

[40]  Wolfram Goessling,et al.  The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML , 2010, Science.

[41]  Kevin S. Smith,et al.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. , 2010, Cancer cell.

[42]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[43]  T. Zimmerman,et al.  Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3 , 2008, Leukemia & lymphoma.

[44]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[45]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Doble,et al.  Functional redundancy of GSK-3α and GSK-3β in wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines , 2007 .